Has Peter Dipasco, MD received payments from drug or device companies?

Yes. Drug and device makers reported $246,626 in general payments to Peter Dipasco, MD across 424 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Peter Dipasco, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Peter Dipasco, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Peter Dipasco, MD

Surgical Oncology · Saint Louis, MONPI 1659491314

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $220,374 of the $246,626 with a category attached, or 89.4%. Medical Device Business Services, Inc. accounts for 60.6% of it on its own, with 59 other manufacturers making up the rest. Among surgical oncology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$246,626in general payments, 2019–2025

Across 424 payments — averaging $581.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medical Device Business Services, Inc.$149K
Johnson & Johnson$79K
Ethicon Endo-surgery Inc.$12K
Histosonics, Inc.$939
Regeneron Healthcare Solutions, Inc.$369
Hologic Sales And Service, LLC$306
plus $4K from 54 others

What the payments were for

Consulting fees$220,37489%
Travel & lodging$14,9776%
Food & beverage$11,0964%
Education$1800%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medical Device Business Services, Inc.	126	$149,369
Johnson & Johnson(3 entities)	124	$79,256
Ethicon Endo-surgery Inc.	6	$12,358
Histosonics, Inc.	5	$939
Regeneron Healthcare Solutions, Inc.	8	$369
Hologic Sales And Service, LLC	3	$306
Merck	13	$294
Tempus AI, Inc	3	$251
AstraZeneca	11	$235
Daiichi Sankyo Inc.	6	$219
Intera Oncology, Inc	1	$175
Stryker	1	$173
Dilon Technologies, Inc.	2	$156
Genentech USA, Inc.	6	$154
Pfizer	6	$141
Takeda Pharmaceuticals U.S.A., Inc.	7	$136
AbbVie	5	$127
Incyte Corporation	7	$126
Novo Nordisk	1	$125
Seagen Inc.	5	$120
Amgen	6	$109
Novartis	6	$107
Siemens Medical Solutions USA, Inc.	1	$106
Lilly USA, LLC	4	$93
Eisai Inc.	4	$81
Bayer	4	$70
Taiho Oncology, Inc.	4	$69
Myriad Genetic Laboratories, Inc.	3	$69
Puma Biotechnology, Inc.	3	$59
Sanofi	2	$48
Springworks Therapeutics, Inc.	2	$47
Mirati Therapeutics, Inc.	2	$42
Sobi, Inc	2	$41
Kyowa Kirin, Inc.	2	$41
ADC Therapeutics America, Inc.	2	$40
Blueprint Medicines Corporation	2	$39
Servier Pharmaceuticals LLC	2	$35
Global Blood Therapeutics, Inc.	2	$32
Galvanize Therapeutics, Inc	1	$29
ETS Wound Care LLC	1	$29
Astellas Pharma US Inc	1	$28
G1 Therapeutics, Inc.	1	$22
Intuitive Surgical	1	$22
Beigene USA, Inc.	1	$22
Medtronic	1	$22
Blue Earth Diagnostics	1	$21
Immunogen, Inc.	1	$20
EMD Serono, Inc.	1	$20
Octapharma USA, Inc.	1	$19
AVEO Pharmaceuticals, Inc.	1	$19
Morphosys, US Inc.	1	$18
Coherus Oncology, Inc.	1	$18
Dova Pharmaceuticals	1	$18
E.r. Squibb & Sons, L.L.C.	1	$17
Melinta Therapeutics, LLC	1	$16
Tersera Therapeutics LLC	1	$16
Pharmacosmos Therapeutics Inc.	1	$16
Emmaus Medical, Inc.	1	$16
Gilead	1	$15
Epizyme, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$246,626 in reported general payments places this provider in the 95th percentile of 24 surgical oncology providers in Missouri.

See all surgical oncology providers in Missouri →

Medicare billing

Part B allowed, 2024

$56,051

Medicare patients

Services billed

154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxycodone Hcl	22	$91

Paid to pharmacies, not to this prescriber.

Other surgical oncology in Saint Louis

Trang NguyenSaint Louis$11K
Rebecca AftSaint Louis$9K
Julie MargenthalerSaint Louis$8K
Taylor BrownSaint Louis$5K
Timothy VreelandSaint Louis$4K
Jennifer KellerSaint Louis$1K
Ashley WilbersSaint Louis$1K
Ashton BrooksSaint Louis$1K
William GillandersSaint Louis$909
Ryan FieldsSaint Louis$385

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →